• Nocodazole Beyond Mitotic Arrest

  2026-09-08

  Nocodazole is more than a mitotic-arrest reagent: it is a reversible microtubule perturbation tool that can sharpen causal interpretation across microtubule dynamics research, cell cycle assays, cancer research, and host–pathogen studies. This article examines how the Wang et al. reovirus inhibitor study turns a negative nocodazole result into a valuable mechanistic boundary, while offering practical guidance for translational experimental design.

• LY364947: A Causal EMT Assay Framework

  2026-09-08

  LY364947 is a TGF-β type I receptor kinase inhibitor for dissecting Smad2 signaling, EMT, fibrosis, and retinal injury. This guide translates recent pancreatic cancer findings into a rigorous assay strategy that separates pathway causality from nonspecific growth effects.

• Ivermectin for Reproducible Cell Assays

  2026-09-07

  Learn how Ivermectin (SKU A2813) can be handled reproducibly in cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects formulation control, assay compatibility, data interpretation, and responsible translational use with practical laboratory recommendations.

• SD 169: Assay-Ready Control of p38 MAPK

  2026-09-07

  SD 169 (indole-5-carboxamide) is a selective p38α/β inhibitor for dissecting inflammatory, autoimmune, metabolic, and nerve-repair signaling. This guide connects its product properties with a newer assay strategy for distinguishing catalytic blockade from kinase dephosphorylation.

• Putting Mammalian Embryonic Cells into Dormancy

  2026-09-05

  This Nature Protocols study establishes noninvasive, in vitro workflows for placing mouse blastocysts, human blastoids, and mouse or human pluripotent stem cells into a reversible diapause-like state through pharmacological mTOR inhibition. Its main contribution is a scalable experimental framework for studying embryonic dormancy while preserving developmental competence and enabling molecular, metabolic, and functional readouts.

• SCH772984 HCl: ERK Control of Agrp

  2026-09-04

  SCH772984 HCl is an ERK1/2 inhibitor that can do more than quantify MAPK pathway suppression. This article examines how selective ERK perturbation can clarify KLF4-dependent Agrp transcription, isoform-specific assay design, and the limits of translating cancer-focused pharmacology into metabolic neuroscience.

• HIV-1 Nuclear Pore Remodeling Licences Infection

  2026-09-04

  The reference study identifies nuclear import through the nuclear pore complex as a major barrier to HIV-1 infection of resting CD4+ T cells. It shows that cell–cell spread activates a CD4–LCK–CDK1 pathway that remodels nucleoporins and enables capsid nuclear import without requiring conventional cell-cycle entry.

• ARID1A-Dependent Melanoma Drug Resistance

  2026-09-03

  The reference study integrates signaling, transcriptional, proteomic, and network-level data to explain how ARID1A loss reshapes early responses to BRAF/MAPK inhibition in melanoma. Its identification of PRKD1, JUN, and NCK1 as resistance-associated nodes provides a practical framework for designing genotype-aware assays that measure adaptive signaling rather than relying only on endpoint proliferation.

• Tomivosertib: MNK1 Inhibitor Workflow for AML

  2026-09-03

  Tomivosertib provides a selective way to connect MNK1/2 activity with eIF4E phosphorylation, AML cell survival, and progenitor growth. This practical guide translates the reference study into reproducible assay design, combination testing, orthogonal validation, and troubleshooting strategies.

• PD98059 for MEK Pathway Experiments

  2026-09-02

  PD98059 is a reversible MEK inhibitor for resolving ERK-dependent changes in proliferation, apoptosis, and oxidative-stress responses. This practical guide connects pathway validation in cultured cells with the ERK–mitochondrial apoptosis workflow used in a cyclophosphamide-induced liver injury study.

• ARID1A-Dependent Resistance in Melanoma Multi-Omics

  2026-09-02

  The reference study integrates multi-omics measurements to show how ARID1A loss rewires signaling, transcription, and immune-related protein programs during BRAF/MAPK inhibitor response. Its identification of PRKD1, JUN, and NCK1 as resistance-associated network nodes provides a mechanistic framework for studying adaptive resistance beyond simple MAPK pathway reactivation.

• LDN-193189 Workflow for BMP Signaling Studies

  2026-09-01

  LDN-193189 enables branch-selective interrogation of ALK2/ALK3-driven BMP signaling, from rapid Smad readouts to epithelial barrier and cell-plasticity assays. This workflow connects mechanistic phosphoprotein measurements with practical endpoints relevant to heterotopic ossification research, mammary biology, and epithelial homeostasis.

• Gastrodin, AT1 Signaling, and Reactive Astrocytes

  2026-09-01

  The reference study identifies a microglia-to-astrocyte signaling framework in which inflammatory conditioned medium alters astrocytic renin–angiotensin system components, SIRT3, phenotype markers, cytokines, and neurotrophic factors. By using azilsartan to perturb AT1 signaling, the work connects gastrodin’s effects with RAS-dependent astrocyte responses while also highlighting the limitations of simple A1/A2 marker classification.

• Elobixibat hydrate: IBAT Research Workflows

  2026-08-31

  Build reproducible gastrointestinal and metabolic assays around Elobixibat hydrate, from transporter blockade through bile acid, GLP-1, motility, and metabolic readouts. Practical handling guidance, assay controls, and troubleshooting help distinguish true IBAT biology from vehicle, precipitation, and tissue-viability artifacts.

• Tomivosertib Workflows for MNK1–eIF4E Studies

  2026-08-31

  Tomivosertib enables direct interrogation of MNK1/2-dependent eIF4E phosphorylation across metabolic, cancer, and neuronal models. This workflow-focused guide connects dose selection and pathway validation with translatome-aware assays and practical troubleshooting.

8459 records 1/564 page Next 12345 下5页 Last page